[go: up one dir, main page]

MA39995B1 - Composés destinés à traiter l'amyotrophie spinale - Google Patents

Composés destinés à traiter l'amyotrophie spinale

Info

Publication number
MA39995B1
MA39995B1 MA39995A MA39995A MA39995B1 MA 39995 B1 MA39995 B1 MA 39995B1 MA 39995 A MA39995 A MA 39995A MA 39995 A MA39995 A MA 39995A MA 39995 B1 MA39995 B1 MA 39995B1
Authority
MA
Morocco
Prior art keywords
compounds
muscular atrophy
spinal muscular
treating spinal
formula
Prior art date
Application number
MA39995A
Other languages
English (en)
Inventor
Luke Green
Hasane Ratni
Nikolai A Naryshkin
Marla L Weetall
Original Assignee
Hoffmann La Roche
Ptc Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53175048&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA39995(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche, Ptc Therapeutics Inc filed Critical Hoffmann La Roche
Publication of MA39995B1 publication Critical patent/MA39995B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des composés représentés par la formule (i) dans laquelle a, r1, r2 et r3 ont la signification indiquée dans la description, ainsi que des sels pharmaceutiquement acceptables de ceux-ci. L'invention concerne également la fabrication des composés représentés par la formule (i), des compositions pharmaceutiques comprenant ces composés, et leur utilisation en tant que médicaments.
MA39995A 2014-05-15 2015-05-11 Composés destinés à traiter l'amyotrophie spinale MA39995B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461993839P 2014-05-15 2014-05-15
PCT/EP2015/060343 WO2015173181A1 (fr) 2014-05-15 2015-05-11 Composés pour le traitement d'une amyotrophie spinale

Publications (1)

Publication Number Publication Date
MA39995B1 true MA39995B1 (fr) 2019-11-29

Family

ID=53175048

Family Applications (2)

Application Number Title Priority Date Filing Date
MA051988A MA51988A (fr) 2014-05-15 2015-05-11 Procédé pour la préparation de composés utiles à traiter l'amyotrophie spinale
MA39995A MA39995B1 (fr) 2014-05-15 2015-05-11 Composés destinés à traiter l'amyotrophie spinale

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA051988A MA51988A (fr) 2014-05-15 2015-05-11 Procédé pour la préparation de composés utiles à traiter l'amyotrophie spinale

Country Status (36)

Country Link
US (1) US9969754B2 (fr)
EP (3) EP3663296B1 (fr)
JP (1) JP6236173B2 (fr)
KR (2) KR102213740B1 (fr)
CN (1) CN106459092B (fr)
AR (2) AR100442A1 (fr)
AU (1) AU2015261046C1 (fr)
BR (1) BR112016026205B1 (fr)
CA (1) CA2948561C (fr)
CL (1) CL2016002836A1 (fr)
CR (1) CR20160518A (fr)
DK (1) DK3143025T3 (fr)
EA (2) EA202090486A3 (fr)
ES (2) ES2761423T3 (fr)
FR (1) FR21C1039I2 (fr)
HR (2) HRP20192159T1 (fr)
HU (2) HUE046491T2 (fr)
IL (2) IL248653B (fr)
LT (1) LTC3143025I2 (fr)
MA (2) MA51988A (fr)
MX (1) MX371050B (fr)
MY (1) MY174284A (fr)
NL (1) NL301128I2 (fr)
NO (2) NO2021035I1 (fr)
NZ (1) NZ725008A (fr)
PE (1) PE20170128A1 (fr)
PH (1) PH12016502081B1 (fr)
PL (2) PL3663296T3 (fr)
PT (1) PT3143025T (fr)
RS (1) RS59718B1 (fr)
SG (1) SG11201609497TA (fr)
SI (2) SI3143025T1 (fr)
TW (1) TWI667239B (fr)
UA (1) UA119670C2 (fr)
WO (1) WO2015173181A1 (fr)
ZA (1) ZA201607026B (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA116981C2 (uk) 2012-02-10 2018-06-11 ПіТіСі ТЕРАП'ЮТІКС, ІНК. Сполуки для лікування спінальної м'язової атрофії
WO2015024876A2 (fr) 2013-08-19 2015-02-26 F. Hoffmann-La Roche Ag Procédé de criblage
US10882868B2 (en) * 2014-05-15 2021-01-05 Hoffmann-La Roche Inc. Compounds for treating spinal muscular atrophy
EP3298017B1 (fr) 2015-05-20 2019-08-14 H. Hoffnabb-La Roche Ag Composés pour le traitement d'une amyotrophie spinale
EP3310169B1 (fr) 2015-05-30 2023-05-17 PTC Therapeutics, Inc. Procédés de modulation de l'épissage de l'arn
EP4360707A3 (fr) * 2015-11-12 2024-08-07 F. Hoffmann-La Roche AG Compositions pour le traitement de l'amyotrophie spinale
AU2016351919B2 (en) * 2015-11-12 2020-11-12 F. Hoffmann-La Roche Ag Compounds for treating amyotrophic lateral sclerosis
PL3386511T3 (pl) 2015-12-10 2021-11-08 Ptc Therapeutics, Inc. Sposoby leczenia choroby huntingtona
CN108137579B (zh) 2015-12-10 2022-01-07 豪夫迈·罗氏有限公司 桥连哌啶衍生物
EP3544435A4 (fr) * 2016-11-28 2020-11-04 PTC Therapeutics, Inc. Procédés de modulation de l'épissage de l'arn
KR20200033249A (ko) 2017-06-05 2020-03-27 피티씨 테라퓨틱스, 인크. 헌팅턴병 치료 화합물
US11608501B2 (en) 2017-06-14 2023-03-21 Ptc Therapeutics, Inc. Methods for modifying RNA splicing
US11395822B2 (en) 2017-06-28 2022-07-26 Ptc Therapeutics, Inc. Methods for treating Huntington's disease
CN111182898B (zh) 2017-06-28 2024-04-16 Ptc医疗公司 用于治疗亨廷顿氏病的方法
CN111132981B (zh) * 2017-09-22 2023-10-31 豪夫迈·罗氏有限公司 制备吡啶并[1,2-a]嘧啶-4-酮衍生物的方法
CA3078137A1 (fr) * 2017-10-03 2019-04-11 F. Hoffmann-La Roche Ag Nouveau traitement de la sma
EA202092001A1 (ru) 2018-03-27 2021-01-29 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Соединения для лечения болезни гентингтона
SG11202012674PA (en) 2018-06-27 2021-01-28 Ptc Therapeutics Inc Heterocyclic and heteroaryl compounds for treating huntington's disease
AU2019294482B2 (en) 2018-06-27 2022-09-01 Ptc Therapeutics, Inc. Heteroaryl compounds for treating Huntington's disease
EP3814360B8 (fr) 2018-06-27 2024-11-06 PTC Therapeutics, Inc. Composés hétéroaryl pour traiter la maladie de huntington
EA202190116A1 (ru) 2018-06-27 2021-08-30 Реборна Биосайенсиз, Инк. Агент для профилактики или лечения спинальной мышечной атрофии
EP3867256A1 (fr) 2018-10-19 2021-08-25 F. Hoffmann-La Roche AG Nouvelles formes de dérivés de pyrido[1,2-a] pyrimidin-4-one, sa formulation et son procédé de fabrication
WO2020249577A1 (fr) 2019-06-12 2020-12-17 F. Hoffmann-La Roche Ag Nouveau traitement de sma
WO2021021775A1 (fr) 2019-07-31 2021-02-04 Teva Pharmaceuticals International Gmbh Formes à l'état solide de risdiplam et leurs procédés de préparation
WO2021207550A1 (fr) * 2020-04-08 2021-10-14 Remix Therapeutics Inc. Composés et procédés de modulation de l'épissage
WO2022048675A1 (fr) * 2020-09-07 2022-03-10 苏州科睿思制药有限公司 Forme cristalline du risdiplam, son procédé de préparation et son utilisation
WO2022162107A1 (fr) 2021-02-01 2022-08-04 Sandoz Ag Forme cristalline de risdiplam
EP4308577B1 (fr) * 2021-03-17 2024-12-25 F. Hoffmann-La Roche AG Nouveaux dérivés de thiadiazolopyrimidone
IL305203A (en) * 2021-03-17 2023-10-01 Hoffmann La Roche New histories of thiazolopyrimidines
EP4308572B1 (fr) * 2021-03-17 2025-04-23 F. Hoffmann-La Roche AG Nouveaux dérivés de thiénopyrimidinone
KR20230145461A (ko) 2021-03-18 2023-10-17 에프. 호프만-라 로슈 아게 리스디플람의 제조 방법
EP4426306A1 (fr) 2021-10-06 2024-09-11 F. Hoffmann-La Roche AG Nouvelle administration combinée
WO2023202501A1 (fr) * 2022-04-18 2023-10-26 深圳市塔吉瑞生物医药有限公司 Composé de pyridopyrimidinone substitué, composition le comprenant et son utilisation
WO2023240236A1 (fr) 2022-06-10 2023-12-14 Voyager Therapeutics, Inc. Compositions et procédés pour le traitement de troubles liés à l'amyotrophie spinale
WO2024069646A1 (fr) * 2022-09-26 2024-04-04 Natco Pharma Limited Procédé amélioré pour la préparation de risdiplam et de ses intermédiaires
EP4601651A1 (fr) 2022-10-14 2025-08-20 Genentech, Inc. Méthodes de traitement de l'amyotrophie spinale
CN120530115A (zh) * 2023-01-21 2025-08-22 哈曼菲诺化学有限公司 利司扑兰的制备方法、新型中间体及其制备方法
WO2024218207A1 (fr) 2023-04-20 2024-10-24 F. Hoffmann-La Roche Ag Dérivés de thiéno[3,2-b]pyridine
WO2024251925A1 (fr) 2023-06-09 2024-12-12 F. Hoffmann-La Roche Ag Système d'expression génique inductible
CN117050096A (zh) * 2023-07-17 2023-11-14 杭州诺澳生物医药科技有限公司 一种利司扑兰的制备方法
WO2025088083A1 (fr) 2023-10-27 2025-05-01 F. Hoffmann-La Roche Ag Nouvelle composition pour le traitement de l'amyotrophie spinale

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20000029843A (ko) * 1996-08-06 2000-05-25 디. 제이. 우드;스피겔 알렌 제이 치환된피리도-또는피리미도-함유6,6-또는6,7-비시클릭유도체
EP2573080A1 (fr) 2007-09-27 2013-03-27 The United States of America, as Represented by the Secretary, Department of Health and Human Services Composés d'Isoindoline pour le traitement d'une amyotrophie spinale et autres utilisations
WO2009151546A2 (fr) 2008-05-27 2009-12-17 Ptc Therapeutics, Inc. Procédés de traitement d'une atrophie musculaire spinale
KR20100012134A (ko) * 2008-07-28 2010-02-08 신호열 마우스
US8986935B2 (en) 2008-08-13 2015-03-24 Ptc Therapeutics, Inc. Methods for treating spinal muscular atrophy
WO2010019326A1 (fr) 2008-08-14 2010-02-18 Cardiac Pacemakers, Inc. Évaluation et adaptation des performances d’une liaison de communication acoustique
EP2797592B1 (fr) * 2011-12-30 2019-08-28 PTC Therapeutics, Inc. Composés de traitement d'une amyotrophie spinale
CA2862084C (fr) * 2012-01-26 2021-05-11 Ptc Therapeutics, Inc. Derives de 1h-isochromen-1-one et leurs compositions pour le traitement de l'amyotrophie spinale
UA116981C2 (uk) * 2012-02-10 2018-06-11 ПіТіСі ТЕРАП'ЮТІКС, ІНК. Сполуки для лікування спінальної м'язової атрофії
AU2013289938A1 (en) 2012-07-13 2015-01-29 Indiana University Research & Technology Corporation Compounds for treatment of spinal muscular atrophy
EP4360707A3 (fr) 2015-11-12 2024-08-07 F. Hoffmann-La Roche AG Compositions pour le traitement de l'amyotrophie spinale

Also Published As

Publication number Publication date
NL301128I2 (nl) 2021-10-25
PL3663296T3 (pl) 2023-08-07
BR112016026205A8 (pt) 2021-07-20
BR112016026205A2 (pt) 2017-08-15
UA119670C2 (uk) 2019-07-25
CL2016002836A1 (es) 2017-04-21
AU2015261046C1 (en) 2019-07-25
MY174284A (en) 2020-04-01
IL248653A0 (en) 2017-01-31
IL270027B (en) 2020-08-31
ES2949660T3 (es) 2023-10-02
EP4241772A3 (fr) 2023-11-15
FR21C1039I2 (fr) 2022-09-02
US9969754B2 (en) 2018-05-15
HRP20192159T1 (hr) 2020-02-21
SI3143025T1 (sl) 2020-01-31
AU2015261046B2 (en) 2019-04-18
MX2016014547A (es) 2017-02-23
CN106459092B (zh) 2019-10-15
CA2948561C (fr) 2019-10-22
PH12016502081B1 (en) 2022-11-23
MX371050B (es) 2020-01-14
ZA201607026B (en) 2022-05-25
EA035068B1 (ru) 2020-04-23
EP3143025B1 (fr) 2019-10-09
EP3663296A1 (fr) 2020-06-10
KR102213740B1 (ko) 2021-02-09
HUS2100037I1 (hu) 2021-10-28
ES2761423T3 (es) 2020-05-19
KR102256013B1 (ko) 2021-05-26
HRP20230637T1 (hr) 2023-09-29
KR20210014219A (ko) 2021-02-08
CR20160518A (es) 2017-02-21
CA2948561A1 (fr) 2015-11-19
BR112016026205B1 (pt) 2021-12-07
AU2015261046A1 (en) 2016-10-27
EA202090486A2 (ru) 2020-06-30
LTC3143025I2 (fr) 2023-11-10
PL3143025T3 (pl) 2020-03-31
AR131260A2 (es) 2025-03-05
EA201692280A1 (ru) 2018-07-31
JP2017515863A (ja) 2017-06-15
TWI667239B (zh) 2019-08-01
NO2021035I1 (no) 2021-09-10
SG11201609497TA (en) 2016-12-29
JP6236173B2 (ja) 2017-11-22
KR20170003687A (ko) 2017-01-09
PE20170128A1 (es) 2017-03-16
FR21C1039I1 (fr) 2021-10-15
PH12016502081A1 (en) 2017-01-09
EA202090486A3 (ru) 2020-08-31
US20170197990A1 (en) 2017-07-13
HUE046491T2 (hu) 2020-03-30
AR100442A1 (es) 2016-10-05
DK3143025T3 (da) 2019-12-09
WO2015173181A1 (fr) 2015-11-19
RS59718B1 (sr) 2020-01-31
NO2025038I1 (no) 2025-08-14
PT3143025T (pt) 2019-12-03
IL248653B (en) 2019-11-28
MA51988A (fr) 2021-01-20
LTPA2021010I1 (fr) 2021-10-11
SI3663296T1 (sl) 2023-08-31
TW201609738A (zh) 2016-03-16
EP3143025A1 (fr) 2017-03-22
NL301128I1 (fr) 2021-09-22
EP4241772A2 (fr) 2023-09-13
CN106459092A (zh) 2017-02-22
NZ725008A (en) 2019-11-29
EP3663296B1 (fr) 2023-05-17

Similar Documents

Publication Publication Date Title
MA39995B1 (fr) Composés destinés à traiter l'amyotrophie spinale
MX2021013075A (es) Oxisteroles y metodos de uso de los mismos.
EP4609866A3 (fr) Oxystérols et leurs procédés d'utilisation
MX2020000261A (es) Nuevos compuestos.
MA37400B1 (fr) Composés hétérocyclyle en tant qu'inhibiteurs de mek
MX384868B (es) Composiciones para tratar atrofia muscular espinal.
MX2020010690A (es) Oxiesteroles y metodos de uso de los mismos.
MA39898B1 (fr) Composés 4-amino-imidazoquinoline
MA40225A (fr) Composés dihydroisoquinolinone substitués
BR112015022643A2 (pt) inibidores diidro-pirrolpiridinona
MA40111A1 (fr) Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1
EA201791019A1 (ru) Полициклические карбамоилпиридоновые соединения и их фармацевтическое применение
CL2021002309A1 (es) Compuestos útiles en la terapia del vih
MX392270B (es) Oxisteroles sustituidos en c7 y metodos de uso de los mismos.
MA40281A (fr) Composés de pyrazole et leur utilisation en tant qu' agents de blocage des canaux calciques de type t
CL2021001388A1 (es) Compuestos útiles en la terapia para el vih
MA39165A1 (fr) Dérivés de benzimidazole-proline pour leurs utilisations dans le traitement du syndrome des etats crepusculaires
EA201890532A1 (ru) Новые аннелированные бензамиды
MA40250A (fr) Dérivés de quinolizinone utilisés comme inhibiteurs de pi3k
MA43913B1 (fr) Modulateurs allostériques positifs du récepteur m1 muscarinique
EA201890684A1 (ru) Производные фториндола в качестве положительных аллостерических модуляторов мускаринового рецептора m1
MA39229A1 (fr) Pyrrolidines, térahydrofuranes et cyclopentanes substitués utiles en tant qu'antagonistes des récepteurs des orexines
MX2020008523A (es) Compuesto que tiene actividad agonista del receptor esfingosina-1-fosfato [(2s,3r,4e)-2-amino-3-hidroxioctadec-4-enil- 1-fosfato (s1p5).
MA39926B1 (fr) Dérivés de dihétérocycle liés à cycloalkyle
MA38857B1 (fr) Dérivés de 1-(pipérazin-1-yl)-2-([1,2,4]triazol-1-yl)-éthanone